Effect of human albumin on TCD vasospasm, DCI, And cerebral infarction in subarachnoid hemorrhage: The Alisah study

Jose I. Suarez, R. H. Martin, E. Calvillo, E. M. Bershad, C. P. Venkatasubba Rao

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Purpose: The neuroprotective effects of human albumin have been studied in animal models of stroke and in humans with various intracranial disorders. We investigated the effect of 25% human albumin (ALB) on mean cerebral blood fl ow velocities (MCBFV), delayed cerebral ischemia (DCI), and cerebral infarction. Methods: We studied patients from the Albumin in Subarachnoid Hemorrhage (ALISAH) pilot clinical trial. We collected data on MCBFV as measured by transcranial Doppler ultrasound (TCD), incidence of DCI, and cerebral infarctions on head computed tomography (CT) scan at 90 days. Results: TCD showed vasospasm in 75% (n = 15), 55% (n = 11), and 29% (n = 2) of subjects in dosage tiers 1, 2, and 3, respectively. DCI was present in 20% (n = 4), 15% (n = 3), and 14% (n = 1) of subjects in dosage tiers 1, 2, and 3, respectively. Cerebral infarctions were seen in 45% (5 of 9), 27% (3 of 18), and 25% (1 of 4) of subjects who had followup head CT scans in dosage tiers 1, 2, and 3, respectively. Conclusions: Higher dosages of ALB were associated with a lower incidence of TCD vasospasm, DCI, and cerebral infarction at 90 days in a dose-dependent manner.

Original languageEnglish (US)
Pages (from-to)287-290
Number of pages4
JournalActa Neurochirurgica, Supplementum
Volume120
DOIs
StatePublished - 2015
Externally publishedYes

Keywords

  • Clinical trials
  • Delayed cerebral ischemia
  • Human albumin
  • Subarachnoid hemorrhage
  • Transcranial Doppler ultrasound

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Effect of human albumin on TCD vasospasm, DCI, And cerebral infarction in subarachnoid hemorrhage: The Alisah study'. Together they form a unique fingerprint.

Cite this